EGFR and cancer: In contrast with YAPoff cancers, YAPon cancers exhibit higher sensitivity to various kinase inhibitors, particularly those in the EGFR/MEK/ERK pathway [14,69,89], as well as genetic vulnerabilities to various genes involved in integrin and extracellular matrix signaling and cytoskeletal organization [14].